AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
"A gorgeous situation": ServiceNow's CEO celebrates a shrinking workforce
2
Intel shares plunge as Israel factory blast compounds weak outlook
3
Cyber startup Cyera eyes $20 billion valuation in new funding talks
4
Stealth Israeli cyber startup valued at over $1.5 billion recruits former 8200 chief
5
Nikesh Arora's pay falls 19.5% to $80 million as Palo Alto Networks board lowers cap on stock awards
More news

Merck

7 stories about Merck
מטה מודרנה ו מטה מרק MERCK

Moderna stock rockets more than 150% after cancer vaccine succeeds in late-stage trial

19.08.26|Reuters
Moderna's personalized mRNA vaccine, combined with Merck's Keytruda, reduced melanoma recurrence and met a secondary goal for preventing the disease from spreading. 
Remepy founders

Merck KGaA and Remepy partner to test ‘Hybrid Drugs’ model

28.04.26|Meir Orbach
Collaboration explores combining medication with app-based therapies in rare tumor programs. 
ינאי עופרן

Biolojic Design lands drug discovery collaboration with Merck potentially worth up to 346 million euros

03.06.24|Sophie Shulman
The partnership will leverage Biolojic Design’s AI-driven discovery platform to design therapeutic antibodies for the treatment of cancer and immunological disorders. 
ד״ר צחון בנטואיץ׳ מייסד משותף של קיוריס Quris AI

Pharma giant Merck expands collaboration with Quris-AI

28.09.23|Meir Orbach
This follows the successful initial collaboration, a preclinical study to assess Quris-AI’s ability to predict drug toxicity in comparison to traditional in vitro and in vivo approaches
מוסף שבועי 18.5.23 פרופסור גל מרקל

Israeli biotech phenom puts death knell on cancer

21.05.23|Roni Dori
At 44, Gal Markel is a biotech bulldozer. After a $95 million exit, the professor of immunology serves as the Deputy Director General of Beilinson Hospital and the Director of the Davidoff Cancer Center, and is also involved in five startups. Now he has raised around $33 million to establish the Samueli Institute, researching ways to help the immune system eradicate cancer cells
Larisa Amir 20

“Pharma companies need to capitalize on early-stage breakthrough innovation.”

29.11.22|CTech
Collaboration is key for pharmaceutical companies as they seek to make the drug development process more efficient and successful, says Larisa Amir, managing director of Merck’s R&D Center.
Larisa Amir

Larisa Amir appointed Managing Director of Merck R&D Center in Israel

13.06.22|CTech
Amir will be responsible for managing the center and will also focus on in-house innovation and external scouting for technologies and biotechnology capabilities in Israeli startups, academia, and hospitals